Subscribe to RSS
Download PDF
DOI: 10.1055/s-0034-1372684
Morbidität und Mortalität von Dialysepatienten – Brauchen wir neue Dialyseverfahren oder neue Dialyseregime?
Morbidity and mortality of patients on dialysis –Do we need new therapeutic procedures or new dialysis regimes?Publication History
Publication Date:
21 March 2014 (online)
Das Überleben von dialysepflichtigen Patienten ist trotz des medizinischen und technischen Fortschritts in den letzten Jahren nur unwesentlich besser geworden. Die kardiovaskuläre Morbidität und Mortalität sind in dieser Patientenpopulation auf der einen Seite überdurchschnittlich hoch, die medikamentösen therapeutischen Möglichkeiten sind auf der anderen Seite begrenzt. In diesem Artikel sollen die aktuell möglichen therapeutischen Verfahren und mögliche Dialyseregime in Bezug auf Hämodialysepatienten vorgestellt und ihre Bedeutung auf die Verbesserung des kardiovaskulären Überlebens diskutiert werden. Des Weiteren wird auf das alternative Eliminationsverfahren der Absorption eingegangen.
The survival of patients on dialysis has become only marginally better despite ongoing medical and technical progress in recent years. Cardiovascular morbidity and mortality are higher than average in this patient population on the one hand, the conservative therapeutic options are limited on the other hand. In this article, the currently possible therapeutic procedures and dialysis regimes are presented in terms of hemodialysis patients and their influence on cardiovascular survival are discussed. Furthermore, the alternate elimination method of hydrophobic protein-bound uremic toxins via absorption will be discussed.
-
Literatur
- 1 Eknoyan G, Beck GJ, Cheung AK. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019
- 2 Baigent C, Landray MJ, Reith C et al. SHARP Investigators. The effects of lowering ldl cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): A randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
- 3 Jaber BL, Gonski JA, Cendoroglo M et al. New polyether sulfone dialyzers attenuate passage of cytokine-inducing substances from pseudomonas aeruginosa contaminated dialysate. Blood Purif 1998; 16: 210-219
- 4 Palmer SC, Rabindranath KS, Craig JC et al. High-flux versus low-flux membranes for end-stage kidney disease. Cochrane Database Syst Rev CD 005016 2012; 9
- 5 Quellhorst E, Schuenemann B, Borghardt J. Clinical and technical aspects of hemofiltration. Artif Organs 1978; 2: 334-338
- 6 Locatelli F, Martin-Malo A, Hannedouche T et al. Membrane Permeability Outcome Study Group. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645-654
- 7 Locatelli F, Altieri P, Andrulli S et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in esrd. J Am Soc Nephrol 2010; 21: 1798-1807
- 8 Grooteman MP, van den Dorpel MA, Bots ML et al. CONTRAST Investigators. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012; 23: 1087-1096
- 9 Maduell F, Moreso F, Pons M et al. ESHOL Study Group. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24: 487-497
- 10 Ok E, Asci G, Toz H et al. Turkish Online Haemodiafiltration S. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013; 28: 192-202
- 11 Foley RN, Gilbertson DT, Murray T, Collins AJ. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 2011; 365: 1099-1107
- 12 Innes A, Charra B, Burden RP et al. The effect of long, slow haemodialysis on patient survival. Nephrol Dial Transplant 1999; 14: 919-922
- 13 Pauly RP, Gill JS, Rose CL et al. Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. Nephrol Dial Transplant 2009; 24: 2915-2919
- 14 Group FHNT, Chertow GM, Levin NW et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363: 2287-2300
- 15 Brettschneider F, Tolle M, von der Giet M et al. Removal of protein-bound, hydrophobic uremic toxins by a combined fractionated plasma separation and adsorption technique. Artif Organs 2013; 37: 409-416